Mediclinic and Adyen
Loading player...
Gerbrand Smit from N-e-F-G Fund Managers chose Mediclinic as his stock pick of the day and Jean Pierre Verster from Protea Capital Management chose Adyen.
Smit said: "I just think that the hospital sector, locally and abroad has been neglected over time. Covid had its challenges for that specific sector so I'm going for Mediclinic tonight, I think they've shown off-shore that their margins are almost back to where they were before Covid."
Verster said: "My stock pick is Adyen, it's a global payments processor - listed in the Netherlands, and if you think about it, if you pay for anything these days with your choice of debit or credit card that could be issued by bank A, B, C or D and the merchant might use their own bank that is also a different bank, so you need someone who is in the middle that sorts out the "plumbing" of the payment system. Adyen is a major player of the "plumbing" payments sector globally and they just got their US banking licence which should boost their profitability."
Smit said: "I just think that the hospital sector, locally and abroad has been neglected over time. Covid had its challenges for that specific sector so I'm going for Mediclinic tonight, I think they've shown off-shore that their margins are almost back to where they were before Covid."
Verster said: "My stock pick is Adyen, it's a global payments processor - listed in the Netherlands, and if you think about it, if you pay for anything these days with your choice of debit or credit card that could be issued by bank A, B, C or D and the merchant might use their own bank that is also a different bank, so you need someone who is in the middle that sorts out the "plumbing" of the payment system. Adyen is a major player of the "plumbing" payments sector globally and they just got their US banking licence which should boost their profitability."
